8-K: Orchestra BioMed Highlights AVIM Therapy Progress at R&D Day, BackBeat Pivotal Trial Enrolling

Orchestra BioMed presented updates on its AVIM therapy for hypertension, including the ongoing BACKBEAT pivotal trial and positive data from previous studies, at its R&D Day.

Summary

• Orchestra BioMed held an R&D Day on June 11, 2024, focusing on their Atrioventricular Interval Modulation (AVIM) therapy for hypertension.
• The company is targeting a greater than $10 billion annual hypertension market and a greater than $4 billion annual artery disease market.
• AVIM therapy is designed to reduce blood pressure by modulating cardiac preload, autonomic nervous system response, and afterload using a dual-chamber pacemaker.
• The BACKBEAT global pivotal study is currently enrolling patients and is a randomized, controlled, double-blind study.
• The study aims to enroll approximately 500 patients across 80 sites globally, with about 50% of patients outside the US.
• Previous studies, MODERATO I and II, showed significant reductions in both 24-hour ambulatory systolic blood pressure (aSBP) and office systolic blood pressure (oSBP) with AVIM therapy.
• The company has a strategic collaboration with Medtronic, which includes a $50 million equity investment and a revenue share per AVIM-enabled device.
• The company estimates a $500 to $1,600 revenue share per AVIM-enabled device based on existing reimbursement structures.
• The company's Virtue Sirolimus AngioInfusion Balloon (SAB) is also being developed for artery disease, with a conditional IDE approved for a coronary pivotal study.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, a strategic partnership, and a clear path to commercialization. The company is addressing large markets with innovative technologies, which is viewed favorably by investors.

Positives

• AVIM therapy has shown statistically significant efficacy data in a double-blind, randomized pilot study.
• The BACKBEAT global pivotal study is now enrolling, indicating progress towards regulatory approval.
• The strategic collaboration with Medtronic provides significant financial and commercial support.
• The partnership-enabled business model is designed to accelerate innovation and yield exceptional future profitability.
• AVIM therapy is compatible with conduction system pacing (CSP) or right ventricular (RV) lead placement.
• The therapy has demonstrated a favorable impact on cardiac hemodynamics in invasive pressure volume loop studies.
• Long-term follow-up data from MODERATO II showed sustained reductions in blood pressure up to 3.6 years.
• The company has a strong intellectual property position for AVIM therapy.

Negatives

• The AVIM therapy is still investigational and not commercially approved.
• The company is operating in a competitive and rapidly changing environment.
• The company is subject to risks related to regulatory approval of its product candidates.
• The company is subject to risks related to the timing of achieving expected regulatory and business milestones.
• The company is subject to risks related to the impact of competitive products and product candidates.

Risks

• The company faces risks related to regulatory approval of its product candidates.
• The timing of achieving expected regulatory and business milestones is uncertain.
• The company is subject to the impact of competitive products and product candidates.
• Changes in domestic and foreign business, market, financial, political, and legal conditions could impact the company.
• The company operates in a very competitive and rapidly changing environment, with new risks emerging from time to time.

Future Outlook

The company is focused on the ongoing BACKBEAT pivotal study and potential regulatory submissions for AVIM therapy, as well as the development of the Virtue SAB for artery disease. The company aims to leverage its partnership-enabled business model to accelerate innovation and achieve profitability.

Management Comments

• David Hochman, CEO, highlighted the company's focus on bringing medical innovation to life.
• David Kandzari, M.D., discussed the unmet treatment need for hypertension in older high-risk patients.
• Vivek Reddy, M.D., presented evidence supporting the AVIM therapy mechanism of action.
• Management emphasized the strategic collaboration with Medtronic and the potential for long-term royalties.

Industry Context

The presentation highlights a renewed interest in device-based therapies for hypertension and artery disease, building on foundational technologies like pacemakers and angioplasty. The company is positioning itself to capitalize on the growing need for effective treatments in these large markets, leveraging partnerships to accelerate development and commercialization.

Comparison to Industry Standards

• The company's AVIM therapy is being developed in the context of a large and established cardiac pacing market, where Medtronic is a global leader with >$1.5B in annual revenues.
• The use of drug-coated angioplasty balloons is becoming the preferred treatment for artery disease, and Orchestra BioMed's Virtue SAB is positioned as a novel non-coated alternative.
• The MODERATO studies are comparable to other pilot studies in the hypertension space, with the BACKBEAT study designed as a global pivotal trial to meet regulatory requirements.
• The company's partnership with Medtronic is similar to other collaborations in the medical device industry, where established companies invest in and commercialize innovative technologies from smaller firms.

Stakeholder Impact

• Shareholders are likely to be positively impacted by the progress of AVIM therapy and the strategic partnership with Medtronic.
• Patients with hypertension and those requiring pacemakers stand to benefit from the potential availability of AVIM therapy.
• Employees may experience increased job security and growth opportunities due to the company's progress.
• Medtronic, as a strategic partner, will benefit from the potential commercial success of AVIM therapy.

Next Steps

• The company will continue enrolling patients in the BACKBEAT global pivotal study.
• The company will pursue regulatory approvals for AVIM therapy.
• The company will continue development of the Virtue SAB for artery disease.
• The company will continue to leverage its partnership with Medtronic for commercialization.

Key Dates

Keywords

AVIM therapy, hypertension, pacemaker, Medtronic, BACKBEAT study, cardiac pacing, blood pressure, clinical trial, MODERATO study, sirolimus, angioplasty, cardiovascular